Dr. Elinor Dehan is a Cancer Genomics scientist at Watson for Genomics, IBM. Dr. Dehan completed her PhD degree in molecular and Cellular Biology from New York University School of Medicine where she elucidated a critical control mechanism of cancer cell death. Following her doctorate work Dr. Dehan joined the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, where she lead target validation and drug discovery projects of oncology targets as part of a partnership with Merck Research Laboratories. In 2013 Dr. Dehan co-founded and served as CEO of PTM Biosciences, a Biotech Startup developing a proteomics-based platform for biomarker identification and drug target discovery in cancer.